SPRUCE BIOSCIENCES, INC.

Spruce Biosciences is a biopharmaceutical company developing therapies for rare neurological and metabolic disorders. The company's primary focus is TA-ERT, a fusion protein engineered as an enzyme replacement therapy for Sanfilippo Syndrome Type B, a rare lysosomal storage disorder. The pipeline also includes Tildacerfont, a candidate for major depressive disorder developed through a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. for commercialization in Japan. Additional programs include SPR202 for Congenital Adrenal Hyperplasia and SPR204, a monoclonal antibody antagonist, for Post-Bariatric Hypoglycemia.

The company operates research and development activities under a license agreement with Eli Lilly and Company covering the research, development, and commercialization of various pharmaceutical compounds. This partnership provides strategic access to Eli Lilly's resources and expertise for advancing the company's clinical programs.

Spruce Biosciences operates with a focused, early-stage structure typical of clinical-stage biopharmaceutical firms, with nine full-time employees based in South San Francisco, California. The company was incorporated in Delaware in 2014 and is publicly traded on the Nasdaq.